YAP1-Driven PLCβ1 Impairs MHC-I Antigen Presentation and Limits Anti-Tumor Immunity in Gastrointestinal Cancer [0.03%]
YAP1驱动的PLCβ1损害胃肠道癌中的MHC-I抗原呈递并限制抗肿瘤免疫反应
Yingjing Zhang,Pengfei Su,Tian Yu et al.
Yingjing Zhang et al.
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet its efficacy in gastrointestinal malignancies is often limited by an immunosuppressive tumor microenvironment. In this study, we identified phospholipase C beta 1 (PL...
Exercise Modulates Microbial Metabolites and Induces Stromal Remodeling in Pancreatic Cancer [0.03%]
运动调节胰腺癌中的微生物代谢产物并诱导细胞外基质重塑
Sumedha Pareek,Robin D Wright,Riccardo Ballarò et al.
Sumedha Pareek et al.
Exercise induces a variety of changes in the tumor microenvironment, with beneficial effects in several tumor types. However, a better understanding of the clinical effects of exercise and mediating mechanisms is needed to maximize the util...
Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy [0.03%]
数学和小鼠模型识别调节性T细胞流入作为获得性PD-1免疫疗法抵抗的关键决定因素
Rachel S Sousa,Shannon N Geels,Claire Murat et al.
Rachel S Sousa et al.
The immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contri...
The Multimodal Pretraining Framework CarHE Predicts Spatial Transcriptomics in Tumors from Routine Pathology Images [0.03%]
基于常规病理图像预测肿瘤空间转录组的多模态预训练框架CarHE
Jiawei Zou,Kai Xiao,Zexi Chen et al.
Jiawei Zou et al.
Spatial transcriptomic analyses provide spatially resolved gene expression data that can provide insights into complex biological processes. However, current spatial transcriptomics approaches remain financially prohibitive and restricted i...
KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma [0.03%]
KRASG12V降解剂为肺癌腺癌提供潜在的治疗机会
Santiago Garcia Borrego,Sandra Misale
Santiago Garcia Borrego
Mutant KRAS inhibition has revolutionized the treatment of lung adenocarcinoma. Unfortunately, responses to this form of targeted therapy are often of limited duration because of the development of resistance. Targeted protein degradation, ...
KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma [0.03%]
KRASG12V降解剂为肺癌腺癌治疗提供潜在机会
Santiago Garcia Borrego,Sandra Misale
Santiago Garcia Borrego
Mutant KRAS inhibition has revolutionized the treatment of lung adenocarcinoma. Unfortunately, responses to this form of targeted therapy are often of limited duration because of the development of resistance. Targeted protein degradation, ...
Immune Circuit Rewiring by HDAC Inhibition Enables Response to Dual Checkpoint Blockade in Metastatic Breast Cancer [0.03%]
HDAC抑制介导的免疫环路重编程可使转移性乳腺癌对双检查点阻断产生反应
Edgar Gonzalez,Jesse Kreger,Yingtong Liu et al.
Edgar Gonzalez et al.
High levels of immune suppression are a common intrinsic mechanism of resistance in metastatic breast cancer that calls for developing immunotherapeutic combinations to broaden treatment responses. Histone deacetylase (HDAC) inhibitors can ...
Motherhood's sentinels: Pregnancy induces tissue-resident memory T cells to curb breast cancer growth [0.03%]
母爱的守护者:妊娠期诱导产生的组织驻留记忆T细胞可抑制乳腺癌生长
Meenakshi Sudhakaran,Kelly Kersten
Meenakshi Sudhakaran
Women who carry a pregnancy to term have long been known to have a reduced lifetime risk of breast cancer, yet the mechanisms underlying this protection remain poorly understood. While parity-induced differentiation and hormonal remodeling ...
Microenvironmental Prostaglandin F2α Antagonizes FSP1 in Cancer Cells to Sensitize Tumors to Ferroptosis and Immunotherapy [0.03%]
微环境中的前列腺素F2α通过抑制癌细胞中的FSP1来增强铁死亡和免疫治疗的疗效
Yu Meng,Qian Zhou,Deze Zhao et al.
Yu Meng et al.
Induction of ferroptosis is a potential strategy for treating cancer and improving the efficacy of immunotherapy. Ferroptosis is driven by excessive peroxidation of polyunsaturated fatty acid-containing phospholipids, suggesting that microe...
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors [0.03%]
抗体药物偶联物与激动剂抗CD137单克隆抗体在实体瘤中的协同作用
Gabriel Gomis,Claudia Herrero,Saioa Arrieta-Aranzueque et al.
Gabriel Gomis et al.
Antibody-drug conjugates (ADCs) show clinical efficacy against several solid malignancies, inducing cytotoxic effects in malignant cells accompanied by changes in the composition of the tumor stroma. The therapeutic effects of some ADCs hav...